PMID- 28210135
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240324
IS  - 1179-2728 (Print)
IS  - 1179-2728 (Electronic)
IS  - 1179-2728 (Linking)
VI  - 4
DP  - 2013
TI  - Practical management of NSCLC patients with long-term bevacizumab treatment: a 
      report of four cases.
PG  - 55-59
LID - 10.2147/LCTT.S45309 [doi]
AB  - INTRODUCTION: Previous research showed that the addition of bevacizumab (a 
      monoclonal antibody against vascular endothelial growth factor [VEGF]) to 
      chemotherapy resulted in a significant efficacy benefit in the treatment of 
      selected patients with advanced nonsquamous non-small cell lung cancer (NSCLC). 
      However, the occurrence and management of adverse events (AEs) during long-term 
      maintenance treatment with bevacizumab is not well known. METHODS: This report 
      presents a descriptive analysis, including the management of AEs, of four 
      patients with advanced NSCLC, who received a relatively long period of 
      bevacizumab maintenance treatment. RESULTS: In patient 1, a 72-year-old retired 
      man with stage cT2N2M1b NSCLC, the only AE related to bevacizumab was a grade 1 
      rhinorrhea. Treatment resulted in a stable disease, with duration of response of 
      38 months. Patient 2 had NSCLC stage cT4N3M1b and developed a cavitation and 
      infection after the first cycle of chemotherapy and bevacizumab, which caused a 
      temporary decrease of her quality of life. Bevacizumab therapy resulted in a 
      partial response, with duration of response of 15 months. A 52-year-old female 
      (patient 3) with stage T2bN2M1a NSCLC is currently under treatment and has so far 
      received 42 cycles of maintenance bevacizumab, with stabilized response (duration 
      of response of 29 months) and no noteworthy AEs. The last patient is a 
      74-year-old male farmer with NSCLC T1N0M1, whose response has lasted for more 
      than 3 years, with until now, no AEs. CONCLUSION: Our retrospective findings of 
      these four patients show the long-term efficacy and safety of bevacizumab 
      treatment in a real-life setting.
FAU - Herder, Gjm
AU  - Herder G
AD  - St Antonius Hospital, Nieuwegein, The Netherlands.
FAU - Codrington, H
AU  - Codrington H
AD  - Haga Hospital, The Hague, The Netherlands.
FAU - Colder, C D
AU  - Colder CD
AD  - St Jansdal Hospital, Harderwijk, The Netherlands.
FAU - Aerts, J G
AU  - Aerts JG
AD  - Amphia Hospital, Breda; Erasmus MC Rotterdam, The Netherlands.
LA  - eng
PT  - Case Reports
DEP - 20131010
PL  - New Zealand
TA  - Lung Cancer (Auckl)
JT  - Lung Cancer (Auckland, N.Z.)
JID - 101632521
PMC - PMC5217443
OTO - NOTNLM
OT  - lung cancer
OT  - maintenance treatment
OT  - non-small cell lung cancer
OT  - safety management
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2013/10/10 00:00
MHDA- 2013/10/10 00:01
PMCR- 2013/10/10
CRDT- 2017/02/18 06:00
PHST- 2017/02/18 06:00 [entrez]
PHST- 2013/10/10 00:00 [pubmed]
PHST- 2013/10/10 00:01 [medline]
PHST- 2013/10/10 00:00 [pmc-release]
AID - lctt-4-055 [pii]
AID - 10.2147/LCTT.S45309 [doi]
PST - epublish
SO  - Lung Cancer (Auckl). 2013 Oct 10;4:55-59. doi: 10.2147/LCTT.S45309. eCollection 
      2013.